GIPNH2
Phase 1Biologic
GIPNH2 is one of 19 biologic programs targeting Metabolism. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Metabolism
#DrugCompanyPhaseTrials
1Ethanol
RochePhase 3
Cymbalta
Jazz PharmaceuticalsPhase 1
Bayer Aspirin
BayerPhase 1
Rapamycin
MMaastricht Radiation Oncology
Phase 2
Tasmar
BBausch Health Americas, Inc.
Phase 1
Atropen
FFresenius Kabi Taiwan Ltd.
Phase 1
Exendin-(9-39)
EEiger BioPharmaceuticals
Phase 1
Obicetrapib
NNewAmsterdam Pharma
Phase 1
Quemliclustat
Arcus BiosciencesPhase 1
Dilantin
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GIPNH2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- FFrederikke Koefoed-Hansen